Working... Menu
Trial record 27 of 123 for:    hypertension "vitamin d"

Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02959723
Recruitment Status : Recruiting
First Posted : November 9, 2016
Last Update Posted : November 9, 2016
Information provided by (Responsible Party):
Rozenn Quarck, PhD, Universitaire Ziekenhuizen Leuven

Brief Summary:
The current aims to combine analysis of different inflammatory biomarkers and BMPR2 mutations, which are currently analyzed in each patient diagnosed with idiopathic or familial PAH, to establish an earlier diagnosis and consequently better orientate the therapeutic strategy in PAH.

Condition or disease
Idiopathic Pulmonary Arterial Hypertension

  Show Detailed Description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
Study Start Date : January 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2020

Primary Outcome Measures :
  1. Circulating Inflammatory Biomarkers: CRP, total cholesterol, HDL-cholesterol, triglycerides, albumin, Lp-PLA2 activity, Thrombin Activatable Fibrinolysis Inhibitor (TAFI), vitamin D [ Time Frame: Changes from baseline in circulating inflammatory biomarkers will be evaluated at 6 months, 12 months and 24 months whenever a right heart catheterization will be performed after starting a treatment ]

Biospecimen Retention:   Samples With DNA
Blood, Lung tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Idiopathic Pulmonary Arterial Hypertension undergoing right heart catheterization and/or lung transplantation

Inclusion Criteria:

  • Idiopathic Pulmonary Arterial Hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02959723

Layout table for location information
UZ Leuven Campus Gasthuisberg Recruiting
Leuven, Belgium, 3000
Contact: Rozenn Quarck, PhD    +3216340962   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven

Layout table for additonal information
Responsible Party: Rozenn Quarck, PhD, Clinical Data Manager, Universitaire Ziekenhuizen Leuven Identifier: NCT02959723     History of Changes
Other Study ID Numbers: UZL-S57114
S57114 ( Other Identifier: UZ Leuven )
First Posted: November 9, 2016    Key Record Dates
Last Update Posted: November 9, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Rozenn Quarck, PhD, Universitaire Ziekenhuizen Leuven:
Pulmonary Arterial Hypertension

Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases